{"nctId":"NCT03387579","briefTitle":"Comparison of Smoflipid to Soy-based Lipid Reduction for Cholestasis Prevention in Surgical Neonates","startDateStruct":{"date":"2018-11-30","type":"ACTUAL"},"conditions":["Cholestasis of Parenteral Nutrition"],"count":24,"armGroups":[{"label":"Smoflipid 20%","type":"EXPERIMENTAL","interventionNames":["Drug: Smoflipid 20% Lipid Emulsion for Injection"]},{"label":"Intralipid 20% Reduction","type":"EXPERIMENTAL","interventionNames":["Drug: Intralipid, 20% Intravenous Emulsion"]},{"label":"Intralipid 20% Historic","type":"OTHER","interventionNames":["Drug: Intralipid, 20% Intravenous Emulsion"]}],"interventions":[{"name":"Smoflipid 20% Lipid Emulsion for Injection","otherNames":[]},{"name":"Intralipid, 20% Intravenous Emulsion","otherNames":["Intralipid 20% Reduction"]},{"name":"Intralipid, 20% Intravenous Emulsion","otherNames":["Intralipid 20% Historic"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria: Neonates with anticipated need for parenteral nutrition (based on primary physicians opinion) for greater than or equal to four weeks and one of the following diagnoses:\n\n* Anatomic: Neonate with intestinal atresia, omphalocele, gastroschisis, or volvulus with or without intestinal resection.\n* Ischemic/perforation: Neonates with spontaneous intestinal perforation or necrotizing enterocolitis requiring surgical intervention.\n\nExclusion Criteria:\n\n* Current weight less than 750 grams\n* AST or ALT greater than 5 times the upper limit of normal within 2 weeks of enrollment\n* Direct bilirubin greater than 2 mg/dL on any consecutive measurements 5 - 7 days apart within 2 weeks of enrollment\n* Severe coagulopathy with INR greater than 95th percentile for age (\\>1.7 at less than 5 days of age, \\> 1.5 older than five days of age)\n* Culture confirmed sepsis with positive blood, urine, or CSF culture within 2 weeks of enrollment\n* Renal failure requiring dialysis\n* Cyanotic heart disease requiring prostaglandin therapy\n* Hypertriglyceridemia (greater than 250mg/dL) at time of enrollment","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Cholestasis","description":"Cholestasis was defined as a direct bilirubin \\> 2 mg/dL on two measurements 5 to 7 days apart.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]}]},{"type":"SECONDARY","title":"Weight Velocity","description":"Weight velocity was calculated as the difference in weight from end to start of study divided by number of days enrolled in study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"28.6","spread":"10.6"},{"groupId":"OG001","value":"23.0","spread":"11.9"},{"groupId":"OG002","value":"24.6","spread":"8.2"}]}]}]},{"type":"SECONDARY","title":"Length Velocity","description":"Length velocity was defined as the difference in length from end of study compared to enrollment divided by the number of days enrolled in study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.08"},{"groupId":"OG001","value":"0.09","spread":"0.65"},{"groupId":"OG002","value":"0.10","spread":"0.08"}]}]}]},{"type":"SECONDARY","title":"Head Circumference (OFC) Velocity","description":"OFC velocity was calculated as difference end and start of study divided by number of days enrolled in study.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.03"},{"groupId":"OG001","value":"0.07","spread":"0.06"},{"groupId":"OG002","value":"0.10","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Average Total Calorie Intake","description":"Total calorie intake, including parenteral and enteral sources, were averaged on a weekly basis.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"114.0","spread":"9.1"},{"groupId":"OG001","value":"101.9","spread":"10.5"},{"groupId":"OG002","value":"109.1","spread":"8.3"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Enteral Autonomy at End of Study","description":"Percentage of patients with enteral autonomy at time of leaving or stopping study was calculated. Enteral autonomy was defined as relying on enteral nutrition only for nutrition intake with no need for parenteral nutrition supplementation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"23","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Essential Fatty Acid Deficiency (EFAD)","description":"Essential fatty acid deficiency was defined as a triene to tetraene ratio greater than 0.05.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"AST Change Over Time","description":"The change of AST over time was calculated and compared between groups. AST change was calculated as AST end - AST enrollment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.3","spread":"25.5"},{"groupId":"OG001","value":"2.9","spread":"62.4"},{"groupId":"OG002","value":"5.1","spread":"49.8"}]}]}]},{"type":"SECONDARY","title":"ALT Change Over Time","description":"The rate of change of ALT over time was compared between groups using mixed model analysis. Change of ALT was calculated as ALT at end of study compared to ALT at enrollment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.7","spread":"14.9"},{"groupId":"OG001","value":"25.3","spread":"53.3"},{"groupId":"OG002","value":"17.2","spread":"51.7"}]}]}]},{"type":"SECONDARY","title":"Alkaline Phosphatase Change Over Time","description":"Alkaline phosphatase was recorded at enrollment and every 2 weeks. The change in alkaline phosphatase was calculated as alkaline phosphatase at end minus enrollment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"107.0","spread":"146.9"},{"groupId":"OG001","value":"166.1","spread":"126.6"},{"groupId":"OG002","value":"150.2","spread":"139.9"}]}]}]},{"type":"SECONDARY","title":"Triglyceride Level Over Time","description":"All enrolled patients had serum triglyceride levels monitored at enrollment and weekly. The triglyceride level changes was calculated using values at the end of study compared to enrollment with mean and standard deviation calculated for each treatment group.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.5","spread":"31.0"},{"groupId":"OG001","value":"013.3","spread":"54.5"},{"groupId":"OG002","value":"13.7","spread":"48.0"}]}]}]},{"type":"SECONDARY","title":"Gamma Glutamyl Transferase (GGT) Over Time","description":"GGT was documented at baseline and regularly intervals with level compared over time between groups. GGT was compared by treatment group for levels at end of study and enrollment.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"99.7"},{"groupId":"OG001","value":"55.7","spread":"73.3"},{"groupId":"OG002","value":"37.3","spread":"121.7"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Retinopathy of Prematurity","description":"The rate of retinopathy of prematurity (ROP) was compared between groups. ROP was diagnosed based on ophthalmologist examination with all stages included.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Bronchopulmonary Dysplasia (BPD) or Chronic Lung Disease","description":"The rate of BPD was documented and compared between groups. BPD was diagnosed based on need for respiratory support at 28 days of age. All levels of severity were included.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"NICU Length of Stay","description":"The length of stay at the level 4 NICU was compared between groups.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.2","spread":"57.6"},{"groupId":"OG001","value":"33.3","spread":"46.0"},{"groupId":"OG002","value":"40.2","spread":"42.2"}]}]}]},{"type":"SECONDARY","title":"Three Year Development- Communication","description":"During the third year of chronological age an Ages and Stages questionnaire (ASQ) was completed by the parents. For each section the range of score possible is 0-60. Higher scores show improved outcomes. Scores are separated into on schedule, monitoring zone, and below cutoff. These thresholds vary by aged screened. Possible screens used for this age group include 36 months, 42 months, and 48 months dependent on exact chronologic age screen completed. At 36 months communication 45-60 is on schedule; 35-40 monitoring, and \\<35 below cutoff. For 42 months on schedule 40-60; monitoring 30-35; below cutoff \\<35. For 48 months on schedule 45-60; monitoring 35-40; below cutoff \\<35.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40.3","spread":"22.4"},{"groupId":"OG001","value":"41.2","spread":"17.7"}]}]}]},{"type":"SECONDARY","title":"Three Year Development: Gross Motor","description":"During the third year of chronological age an Ages and Stages questionnaire (ASQ) was completed by the parents. For each section the range of score possible is 0-60. Higher scores indicate improved outcome, there are three possible scoring categories on schedule (normal), monitoring zone, below cutoff. Score thresholds by possible screens include: 36 months on schedule 50-60; monitoring 40-45; below cutoff \\<40. 42 months on schedule 50-60; monitoring 40-45; below cutoff \\<40. 48 months on schedule 45-60; monitoring 35-40; below cutoff \\<35.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"43.0","spread":"24.2"},{"groupId":"OG001","value":"54.1","spread":"8.19"}]}]}]},{"type":"SECONDARY","title":"Three Year Development: Fine Motor","description":"During the third year of chronological age an Ages and Stages questionnaire (ASQ) was completed by the parents. For each section the range of score possible is 0-60. Higher scores show improved outcomes with three scoring categories: on schedule (normal), monitoring zone, and below cutoff. These thresholds vary by each category and screening age. Based on the possible screens for chronological age the score categories are: 36 months: 35-60 on schedule; 20-30 monitoring; \\<20 below cutoff. 42 months: 35-60 on schedule; 20-30 monitoring; \\<20 below cutoff. 48 months: 35-60 on schedule; 20-30 monitoring; \\<20 below cutoff.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.2","spread":"21.6"},{"groupId":"OG001","value":"34.9","spread":"19.1"}]}]}]},{"type":"SECONDARY","title":"Three Year Development: Problem Solving","description":"During the third year of chronological age an Ages and Stages questionnaire (ASQ) was completed by the parents. For each section the range of score possible is 0-60. Higher scores indicate improved outcomes with three possible score categories: on schedule (normal), monitoring zone, and below cutoff. Category thresholds vary by outcome category and age of screen. There are three possible screens that were used for this population, chosen based on chronologic age. The score categories based on age are: 36 months: 45-60 on schedule; 35-40 monitoring; \\<35 below cutoff. 42 months: 40-60 on schdule; 30-35 monitoring; \\<30 below cutoff. 48 months: 45-60 on schedule; 35-40 monitoring; \\<35 below cutoff","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.9","spread":"19.5"},{"groupId":"OG001","value":"47.3","spread":"11.1"}]}]}]},{"type":"SECONDARY","title":"Three Year Development: Personal Social","description":"During the third year of chronological age an Ages and Stages questionnaire (ASQ) was completed by the parents. For each section the range of score possible is 0-60. Higher scores indicate improved outcomes with three score categories possible including on schedule (normal), monitoring zone, and below cutoff. These thresholds vary based on outcome measure and age of screen completed. Screen used depends on chronological age at screen. Score thresholds for each age include: 36 months: 45-60 on schedule; 35-40 monitoring; \\<35 below cutoff. 42 months: 45-60 on schedule; 35-40 monitoring; \\<35 below cutoff. 48 months: 40-60 on schedule; 30-40 monitoring; \\<30 below cutoff.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.5","spread":"20.6"},{"groupId":"OG001","value":"47.1","spread":"10.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":12},"commonTop":["Anemia","Hypoalbuminemia","Elevated GGT","Hypophosphatemia","Hypoglycemia"]}}}